Konnakkaparambil Ramakrishnan Kavitha, George Mithila
Department of Psychiatry, Government TD Medical College, Alapuzha, Kerala, India
Department of Psychiatry, Government Medical College, Ernakulam, Cochin, Kerala, India.
BMJ Case Rep. 2021 Mar 5;14(3):e239569. doi: 10.1136/bcr-2020-239569.
Deep vein thrombosis has been recognised as a complication of antipsychotic treatment and is reported to be more common with atypical antipsychotics. Risperidone is a second-generation atypical antipsychotic and there have been case reports of risperidone-associated deep vein thrombosis, most of them reporting the complication from 2 weeks to a few months of initiation of therapy. Here, we are reporting a case of deep vein thrombosis in a male patient in his early forties with paranoid schizophrenia, which presented on the fourth day of starting risperidone therapy. This case is being reported to highlight the fact that deep vein thrombosis can occur as early as fourth day of initiation of risperidone therapy, that too at a low dose (2 mg/day). The case also emphasises the importance of monitoring these patients for this rare but potentially serious adverse effect from the first day itself after initiation of a new antipsychotic.
深静脉血栓形成已被确认为抗精神病药物治疗的一种并发症，据报道在非典型抗精神病药物中更为常见。利培酮是第二代非典型抗精神病药物，已有利培酮相关深静脉血栓形成的病例报告，其中大多数报告该并发症出现在治疗开始后的2周 至几个月。在此，我们报告一例40岁出头患有偏执型精神分裂症的男性患者发生深静脉血栓形成的病例，该病例出现在开始使用利培酮治疗的第四天。报告该病例是为了强调深静脉血栓形成可在开始利培酮治疗的第四天就出现，而且是在低剂量（2毫克/天）的情况下。该病例还强调了在开始使用新的抗精神病药物后从第一天起就对这些患者监测这种罕见但可能严重的不良反应的重要性。
